Lumida
/SLNO
⌘K
Soleno Therapeutics Inc

Soleno Therapeutics Inc

SLNO
$53.01USD+0.04%+0.02 today

MARKET CAP

2.8B

P/E (TTM)

29.3x

FWD P/E

DAY RANGE

$53 – $53

52W RANGE

$29
$90

AI Summary

Stalk
StalkMedium

SLNO remains in an early Stage 1 consolidation with its 9/20 EMAs repaired and supporting price. Medium-term directional asymmetry is bullish, driven by multiple continuation patterns signaling demand dominance. However, price is extended and overbought with exhaustion visible in RSI and options. Execution should be deferred until a shallow pullback into the rising EMA cluster emerges to confirm support before engaging.

  • Q4 net revenue $91.7M (+40% sequential) and FY25 sales of $190.4M
  • 1,250 patient start forms (~12.5% addressable US market) with 859 active patients
  • Lag from patient start forms to active dosing may pressure quarterly revenue
Full analysis →

Buying

1

institutions

Selling

12

institutions

New Positions

0

this quarter

Filing Period

Q1 2026

latest 13-F

13-F Holdings

InstitutionActionShares HeldValueChangeChg %Weight
JH

Janus Henderson Group Plc

Q1 2026

BUY7.25 M242.58 M+68.81 K-27.0%0.06%
BI

Blackrock, Inc.

Q2 2026

SELL0.000.00+-3.74 M-100.0%0.00%
WP

Woodline Partners LP

Q2 2026

SELL0.000.00+-2.22 M-100.0%0.00%
MM

Millennium Management LLC

Q2 2026

SELL0.000.00+-626.51 K-100.0%0.00%
CA

Citadel Advisors LLC

Q2 2026

SELL0.000.00+-515.75 K-100.0%0.00%
RT

Renaissance Technologies LLC

Q2 2026

SELL0.000.00+-447.30 K-100.0%0.00%
BH

Brevan Howard Capital Management LP

Q2 2026

SELL0.000.00+-135.62 K-100.0%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

SELL0.000.00+-51.48 K-100.0%0.00%
AC

Adar1 Capital Management, LLC

Q2 2026

SELL0.000.00+-46.83 K-100.0%0.00%
AC

Aqr Capital Management LLC

Q2 2026

SELL0.000.00+-21.15 K-100.0%0.00%
MG

Man Group Plc

Q2 2026

SELL0.000.00+-20.68 K-100.0%0.00%
FC

Farallon Capital Management LLC

Q1 2026

SELL0.000.00+-5.00 K-100.0%0.00%
RC

Rockefeller Capital Management L.P.

Q2 2026

SELL0.000.00+-344.00-100.0%0.00%